(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 36.62% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Geron's revenue in 2026 is $204,559,000.On average, 7 Wall Street analysts forecast GERN's revenue for 2026 to be $154,842,516,303, with the lowest GERN revenue forecast at $146,766,625,552, and the highest GERN revenue forecast at $162,063,917,420. On average, 7 Wall Street analysts forecast GERN's revenue for 2027 to be $224,101,149,793, with the lowest GERN revenue forecast at $201,383,290,051, and the highest GERN revenue forecast at $278,820,610,038.
In 2028, GERN is forecast to generate $344,854,027,015 in revenue, with the lowest revenue forecast at $275,274,156,820 and the highest revenue forecast at $504,309,502,395.